[4-[(11R,13S,17R)-17-羟基-13-甲基-3-氧代-17-丙-1-炔基-1,2,6,7,8,11,12,14,15,16-十氢环戊烯并[a]菲-11-基]苯基]-三甲基氯化铵 | 109345-60-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: [4-[(11R,13S,17R)-17-羟基-13-甲基-3-氧代-17-丙-1-炔基-1,2,6,7,8,11,12,14,15,16-十氢环戊烯并[a]菲-11-基]苯基]-三甲基氯化铵
• 英文名称: Mifepristone methochloride
• 英文别名: [4-[(11R,13S,17R)-17-hydroxy-13-methyl-3-oxo-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-11-yl]phenyl]-trimethylazanium;chloride
• CAS: 109345-60-0
• 化学式: C30H38ClNO2
• 分子量: 480.1
• InChiKey: BOYVMWBEQCZPAM-YHBHNODXSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.54
• 重原子数：
  34
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Treatment of Heart Failure and Sudden Cardiac Death
  申请人：Rhode Island Hospital

  公开号：US20150005269A1

  公开（公告）日：2015-01-01

  A method of reducing heart failure or preventing sudden cardiac death in a subject in need thereof is carried out by administering a composition comprising a compound that increases cellular level of Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a (SERCA2a). The invention represents a significant breakthrough in the treatment or prevention of chronic heart failure. The invention is based upon the discovery that a Mifepristone molecule increases the cellular level of SERCA2a protein.
• [EN] TREATMENT OF HEART FAILURE AND SUDDEN CARDIAC DEATH<br/>[FR] TRAITEMENT DE L'INSUFFISANCE CARDIAQUE ET DE LA MORT SUBITE D'ORIGINE CARDIAQUE
  申请人：RHODE ISLAND HOSPITAL

  公开号：WO2013103687A2

  公开（公告）日：2013-07-11

  A method of reducing heart failure or preventing sudden cardiac death in a subject in need thereof is carried out by administering a composition comprising a compound that increases cellular level of Sarco/endoplasmic reticulum Ca2+-ATPase 2a (SERCA2a). The invention represents a significant breakthrough in the treatment or prevention of chronic heart failure. The invention is based upon the discovery that a Mifepristone molecule increases the cellular level of SERCA2a protein.